Get started
Author

Yayuan Fu

Observed institution: Simcere Pharmaceutical (China)
OpenAlex ID: A5033611704
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment
2024 · Shuai Wang, Yanqiu Wang, et al. · mAbs · 14
3C conjugates: a highly sensitive platform for antibody internalization assessment in ADC development
2025 · Changyan Chen, Yutian Zhang, et al. · mAbs · 1
PDF
Abstract 2965: SCR-A006, an innovative and potential best-in-class EGFR/cMet bispecific antibody-drug conjugate
2025 · Yayuan Fu, Chaochao Cen, et al. · Cancer Research · 1
Abstract 2964: SCR-A002, a novel FGFR2b-targeting ADC for solid tumors
2025 · Yayuan Fu, Yuanjie Ge, et al. · Cancer Research · 1
Abstract 4328: Preclinical development of SCR-A008: A CDH17-targeted ADC for gastrointestinal cancer
2025 · Guangcun Cheng, Hui Zheng, et al. · Cancer Research · 1
Abstract 1560: SCR-A0011, a novel bispecific ADC targeting cMET and B7H3, exhibits potent anti-tumor efficacy
2025 · Yayuan Fu, Guangcun Cheng, et al. · Cancer Research · 1
Abstract 2115: SIM0680, a potent antibody-drug conjugate for the treatment of solid tumors expressing ENPP3
2025 · Abdullah Emran, Yutian Zhang, et al. · Cancer Research · 1
SCR-A002, a novel FGFR2b-targeting antibody-drug-conjugate for solid tumors.
2024 · Yayuan Fu, Yuanjie Ge, et al. · Journal of Clinical Oncology · 1
PDF
Abstract 1882: SCR-9171, a MUC17-targeted bispecific T cell engager molecule for gastrointestinal cancer
2023 · Guangcun Cheng, Yayuan Fu, et al. · Cancer Research · 1
Abstract 5858: SCR-M030, an innovative and potential first-in-class trispecific T cell engager targeting PSMA and STEAP1 for mCRPC
2026 · Changyan Chen, Yayuan Fu, et al. · Cancer Research
Abstract 3185: SCR-A019, a first-in-class biparatopic ADC targeting MSLN, with a novel topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models
2026 · Qiong Wang, Yayuan Fu, et al. · Cancer Research
Abstract 5540: SCR-M015, a PD-1/VEGF bispecific antibody exhibits potent anti-tumor efficacy in preclinical studies
2026 · Qiong Wang, Yayuan Fu, et al. · Cancer Research
Abstract 1717: SCR-A014, a novel bispecific ADC targeting B7H3 and DLL3 for SCLC therapy, exhibits potent anti-tumor efficacy
2026 · Guangcun Cheng, Yayuan Fu, et al. · Cancer Research
Progress and Prospects of Combined Targets in Macromolecular Drugs
2026 · Yayuan Fu, Qiong Wang, et al. · 中国科学基金
PDF
A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes
2025 · Xiyuan Wang, Kaiwen Chi, et al. · Translational Lung Cancer Research
Abstract 5449: Preclinical development of SCR-A003, a novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting LIV-1 for solid cancer
2025 · Yayuan Fu, Changyan Chen, et al. · Cancer Research
Abstract 1883: A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment
2023 · Yayuan Fu, Shumei You, et al. · Cancer Research
Abstract 6357: Generation of a mutant SIRPa fusion protein with highly-improved affinity and favorable safety profile
2023 · Yingying Hu, Yayuan Fu, et al. · Cancer Research
Abstract 6343: A multispecific T cell engager binding to both membrane proximal and membrane distal epitopes of MSLN with low affinity CD3 for the treatment of AML and solid tumors
2022 · Cuiqing Yang, Xiaohui Shao, et al. · Cancer Research
Works count: 19
Citation count: 22
H-index: 1
I10-index: 1
Year
Topic
Type